Innovimmune Biotherapeutics, Inc.'s Preclinical Data On Highly Selective ROR Gamma Inhibitor Prevents Multiple Sclerosis In Mice
1/15/2014 8:09:46 AM
NEW YORK, Jan. 15, 2014 (GLOBE NEWSWIRE) -- Specialty drug discovery company, Innovimmune Biotherapeutics Holding, LLC presented data at the XXI World Congress of Neurology in Vienna, Austria (September 22-24, 2013) that demonstrated robust efficacy in preventing multiple sclerosis [MS] in a preclinical mouse model following treatment with its proprietary oral small molecule Retinoic acid receptor-related Orphan Receptor ROR gamma (t) [ROR gamma t] modulators from their INV-17 portfolio.
Help employers find you! Check out all the jobs and post your resume.
comments powered by